A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.
Sergio Fragoso-SaavedraDavid A Iruegas-NunezAlejandro Quintero-VillegasH Benjamín García-GonzálezIsaac NuñezSergio L Carbajal-MorelosBelem M Audelo-CruzSarahi Arias-MartínezYanink Caro-VegaJuan José CalvaVerónica Luqueño-MartínezAlejandra González-DuarteBrenda Crabtree-RamírezJosé C CrispínJuan Sierra-MaderoPablo F Belaunzarán-ZamudioSergio Iván Valdés-FerrerPublished in: BMC infectious diseases (2020)
ClinicalTrials.gov NCT04343963 (registered on April 14, 2020).
Keyphrases
- double blind
- placebo controlled
- phase iii
- clinical trial
- mechanical ventilation
- phase ii
- study protocol
- open label
- acute respiratory distress syndrome
- intensive care unit
- coronavirus disease
- early onset
- randomized controlled trial
- sars cov
- cardiovascular events
- phase ii study
- respiratory failure
- cardiovascular disease
- squamous cell carcinoma
- risk factors
- coronary artery disease
- cross sectional
- drug induced